US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Inside Information: Optomed receives a large order in the US

Optomed Plc Stock Exchange Release 18 June 2026 at 17.30, Helsinki Inside Information: Optomed receives a large order in the US Optomed has received an order of approximately USD 2.1 million (EUR 1.8 million) from a US screening service provider and distributor in the US. The order is for traditional capital sales and does not include AI service or a recurring revenue component.   The order is expected to have a positive effect on the Devices segment for the second half of the year.   Outlook unchanged: Optomed expects its full year 2026 revenue to grow compared to 2025.

Decisions of the Organization Meeting of Optomed’s Board of Directors

Optomed Plc Stock Exchange Release 8 May 2026 at 20.00 , Helsinki Decisions of the Organization Meeting of Optomed’s Board of Directors At its meeting held after the Annual General Meeting, the Board of Directors elected from among its members Petri Salonen as its Chair. The committee members were elected as follows:   Audit Committee: ·          Reijo Tauriainen (Chair) ·          Kristiina Leppänen ·          Catherine Calarco ·          Sameer Badlani   Remuneration Committee: ·          Ty Lee (Chair) ·          Seppo Mäkinen ·          Leana Wen

Decisions of the Annual General Meeting

Optomed Plc Stock Exchange Release 8 May 2026 at 2.30 p.m., Helsinki Decisions of the Annual General Meeting   The Annual General Meeting held on 8 May 2026 adopted the financial statements for the financial period ended on 31 December 2025, discharged the members of the Board of Directors and the CEO from liability for the financial period ended on 31 December 2025 and adopted the Company’s Remuneration Report.   The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that no dividend will be paid for the year 2025.   The number of

Optomed Plc: Interim report January – March 2026

Optomed Plc Stock Exchange Release 6 May 2026 at 9.00, Helsinki  Optomed Plc: Interim report January – March 2026 January – March 2026 · Revenue decreased by 16.7 percent to EUR 3.4 (4.0) million. · Currency-adjusted revenue decrease was 15.4 percent. · Devices segment revenue decreased by 30.2 percent to EUR 1.1 (1.5) million. · Devices segment currency-adjusted revenue decrease was 26.8 percent. · Software segment revenue decreased by 8.4 percent to EUR 2.3 (2.5) million. · EBITDA amounted to EUR -0.7 (-0.7) million corresponding to -20.9 (-18.3) percent of

Optomed’s January-March 2026 interim report will be published on 6 May 2026

Optomed Plc Press Release 29 April 2026 at 9.00, Helsinki Optomed’s January-March 2026 interim report will be published on 6 May 2026 Optomed will publish its January-March 2026 interim report on 6 May 2026 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance by email to sakari.

Notice Of The Annual General Meeting Of Optomed Plc

Optomed Plc  Stock Exchange Release             9 April 2026 at 13.00, Helsinki NOTICE OF THE ANNUAL GENERAL MEETING OF OPTOMED PLC   Notice is given to the shareholders of Optomed Plc (“Optomed” or the “Company”) of the Annual General Meeting (the “General Meeting”) to be held on Friday, 8 May 2026 at 10:00 a.m. (EEST) at Life Science Center Keilaniemi, Keilaranta 16 C, FI-02150 Espoo, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 9:30 a.m. (EEST).   Shareholders may exercise their voting rights

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc Stock Exchange Release 27 February 2026 at 9.00, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from OP-Rahastoyhtiö Oy (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held the by the Notifier is 4.99 per cent of all of the registered shares in Optomed on 25 February 2026.   The total number

Optomed Annual Report 2025 published

Optomed Plc Stock Exchange Release 25  February 2026 at 9.00, Helsinki Optomed Annual Report 2025 published Optomed's Annual Report 2025 has been published. The Annual Report includes the company's consolidated and parent company financial statements, the report of the board of directors, the auditor’s report, corporate governance statement and remuneration report for governing bodies.   Optomed's Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. KPMG Oy Ab, authorised public accountants, has provided an

Optomed Plc: Financial Statements Bulletin January – December 2025

Optomed Plc        Stock Exchange Release   10 February 2026 at 9.00, Helsinki Optomed Plc: Financial Statements Bulletin January – December 2025 October – December 2025 · Revenue decreased by 5.6 percent to EUR 4.8 (5.1) million. The company received a large order of EUR 1.5 million during the comparison period. · Currency-adjusted revenue decreased by 3.9 percent. · Devices segment revenue decreased by 6.7 percent to EUR 2.4 (2.6) million. Segment revenue during Q3 2025 was EUR 2.3 million. · Devices segment currency-adjusted revenue decreased by 3.3 percent. ·

Optomed’s Financial Statements Bulletin will be published on 10 February 2026

Optomed Plc Press Release 3 February 2026 at 9.00, Helsinki Optomed’s Financial Statements Bulletin will be published on 10 February 2026 Optomed will publish its Financial Statements Bulletin 2025 on 10 February 2026 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance by email

Proposal of Optomed’s Nomination Board

Optomed Plc Stock Exchange Release 29 January 2026 at 13:30, Helsinki Proposal of Optomed’s Nomination Board Optomed’s Nomination Board proposes the following to the next Annual General Meeting:   Number of Board members The Nomination Board proposes, that the number of members of the Board of Directors for the term expiring at the end of the Annual General Meeting 2027 is eight.   Composition of the Board of Directors The Nomination Board proposes to the Annual General Meeting that Sameer Badlani, Catherine Calarco, Ty Lee, Seppo Mäkinen, Petri Salonen, Reijo

Optomed Achieves ISO 27001 Certification for Information Security Management Systems

Optomed Plc Press Release 21 Jan 2026 at 11.00, Helsinki   Optomed Achieves ISO 27001 Certification for Information Security Management Systems Optomed, a global leader in AI-enabled handheld retinal screening technology, is proud to announce that it has achieved ISO 27001 certification, the internationally recognized standard for Information Security Management Systems (ISMS). ISO 27001 is a globally accepted framework for managing sensitive company and customer information, ensuring confidentiality, integrity, and availability of data through robust risk management practices

Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening

Optomed Plc Press Release 12 January 2026 at 9.00, Helsinki   Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening Optomed and Aireen a.s., a pioneer in AI-driven medical diagnostics, today announced a strategic partnership to deliver AI-powered handheld imaging solutions. As part of this collaboration, Optomed’s flagship handheld fundus camera, Optomed Lumo®, has been approved for integration with Aireen’s AI algorithm for diabetic retinopathy screening in the EU market.  This regulatory milestone enables

New shares subscribed for in Optomed Plc’s directed share issue have been registered in the Finnish Trade Register

OPTOMED PLC STOCK EXCHANGE RELEASE 12 December 2025, at 3.45 p.m. EET   New shares subscribed for in Optomed Plc’s directed share issue have been registered in the Finnish Trade Register A total of 1,760,000 new shares subscribed for in Optomed Plc’s directed share issue have been registered into the Finnish Trade Register today, on 12 December 2025. After the registration of the new shares, the company will have 21,453,297 shares in total of which 22,042 shares in treasury. The new shares produce the right to dividends and other distribution of assets as well as other

Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

OPTOMED PLC INSIDE INFORMATION   10 December 2025, at 10 p.m. EET   Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. The Board of Directors (the “Board”) of Optomed Plc (“

Optomed Plc: Interim Report, January – September 2025

Optomed PlcStock Exchange Release 6 November 2025 at 9.00, Helsinki Optomed Plc: Interim Report, January – September 2025   July– September 2025   · Revenue increased by 42.1 percent to EUR 4.4 (3.1) million. · Currency-adjusted revenue growth was 47.0 percent. · Devices segment revenue increased by 183.6 percent to EUR 2.3 (0.8) million. · Devices segment currency-adjusted revenue growth was 202.5 percent. · Software segment revenue decreased by 8.0 percent to EUR 2.1 (2.3) million. · EBITDA amounted to EUR -0.5 (-0.8) million corresponding to -12.1 (-26.2)

Optomed’s January-September 2025 interim report will be published on 6 November 2025

Optomed Plc Press Release 30 October 2025 at 9.00, Helsinki Optomed’s January-September 2025 interim report will be published on 6 November 2025 Optomed will publish its January-September 2025 interim report on 6 November 2025 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance

Optomed Plc - Managers' transactions - Knuutti

Optomed Plc - Managers' Transactions – 26 September  2025 at 16.30 EET Optomed Plc - Managers' transactions - Knuutti____________________________________________ Person subject to the notification requirementName: Knuutti, SakariPosition: Chief Financial OfficerIssuer: Optomed PlcLEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATIONReference number: 7437009IVYWGEE4S7B77_20250926113812_74____________________________________________ Transaction date: 2025-09-26Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT

Optomed Plc - Managers' transactions - Himberg

Optomed Plc - Managers' Transactions – 26 September 2025 at 16.30 EET Optomed Plc - Managers' transactions - Himberg____________________________________________ Person subject to the notification requirementName: Himberg, JuhoPosition: Chief Executive OfficerIssuer: Optomed PlcLEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATIONReference number: 7437009IVYWGEE4S7B77_20250926113812_71____________________________________________ Transaction date: 2025-09-26Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT

Optomed Plc - Managers' transactions - Myllylä

Optomed Plc - Managers' Transactions – 26 September  2025 at 16.30 EET Optomed Plc - Managers' transactions - Myllylä____________________________________________ Person subject to the notification requirementName: Myllylä, MarkkuPosition: Other senior managerIssuer: Optomed PlcLEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATIONReference number: 7437009IVYWGEE4S7B77_20250926113812_73____________________________________________ Transaction date: 2025-09-26Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT

Optomed Plc - Managers' transactions - Piila

Optomed Plc - Managers' Transactions – 26 September 2025 at 16.30 EETOptomed Plc - Managers' transactions - Piila____________________________________________ Person subject to the notification requirementName: Piila, LauraPosition: Other senior managerIssuer: Optomed PlcLEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATIONReference number: 7437009IVYWGEE4S7B77_20250926113812_72____________________________________________ Transaction date: 2025-09-26Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Optomed’s Board has resolved upon a new option plan

Optomed Plc Stock Exchange Release 23 September 2025 at 9.00, Helsinki Optomed’s Board has resolved upon a new option plan Optomed’s board of directors has resolved upon a new option plan. The resolution is based on the authorization given by the general meeting of 9 May 2025.   Option plan 2025A: The total number of options is 190,000 and each option entitled to one share of the company. The options are offered to certain key employees. The purpose of the plan is to retain and incentifize the CEO and certain other key employees. The subscription price is EUR 3.77. The

Composition of Optomed’s Nomination Board

Optomed Plc Stock Exchange Release 9 September 2025 at 9.30, Helsinki Composition of Optomed’s Nomination Board According to Optomed’s shareholder register of 1st of September 2025, the shareholders represented in the shareholders’ Nomination Board are OP-Rahastoyhtiö Oy (OP funds), SP-Rahastoyhtiö Oy (SP Funds) and Danske Invest Rahastoyhtiö Oy (Danske Funds). These shareholders have appointed the following persons to the Nomination Board:   · Vesa Vanha-Honko, OP funds · Petteri Vaarnanen, SP funds · Ville Kivipelto, Danske Funds Petri Salonen, Chairman of Optomed’s

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media